| scholarly article | Q13442814 |
| P50 | author | Jonas Hermansson | Q80838679 |
| Thomas Kahan | Q51283808 | ||
| P2093 | author name string | Thomas Kahan | |
| Jonas Hermansson | |||
| P2860 | cites work | Becoming the Framingham Study 1947-1950 | Q81590750 |
| Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement | Q21562278 | ||
| Prediction of Coronary Heart Disease Using Risk Factor Categories | Q22241923 | ||
| Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study | Q24630111 | ||
| Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report | Q27861020 | ||
| Primary prevention of cardiovascular disease: cost-effectiveness comparison | Q28217877 | ||
| Pravastatin. A pharmacoeconomic review of its use in primary and secondary prevention of coronary heart disease | Q33584131 | ||
| 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by repres | Q34046881 | ||
| Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes | Q34479098 | ||
| Cost-effectiveness of rosuvastatin in comparison with generic atorvastatin and simvastatin in a Swedish population at high risk of cardiovascular events | Q35752981 | ||
| Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. | Q35902547 | ||
| Economic evaluation of statins in high-risk patients treated for primary and secondary prevention of cardiovascular disease in Greece | Q36039663 | ||
| Comparison of the prediction by 27 different factors of coronary heart disease and death in men and women of the Scottish Heart Health Study: cohort study | Q36246409 | ||
| AdViSHE: A Validation-Assessment Tool of Health-Economic Models for Decision Makers and Model Users | Q36698876 | ||
| Cost-effectiveness of eplerenone plus standard treatment compared with standard treatment in patients with myocardial infarction complicated by left ventricular systolic dysfunction and heart failure in the Netherlands | Q36813366 | ||
| Population-based health-economic evaluation of the secondary prevention of coronary heart disease in Finland | Q37628751 | ||
| Cost-effectiveness of rosuvastatin 20 mg for the prevention of cardiovascular morbidity and mortality: a Swedish economic evaluation of the JUPITER trial | Q38461504 | ||
| A general cardiovascular risk profile: The Framingham study | Q39774351 | ||
| Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease | Q40287836 | ||
| Cost-effectiveness of pravastatin in secondary prevention of coronary heart disease: comparison between Belgium and the United States of a projected risk model | Q40847554 | ||
| Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation | Q43742848 | ||
| The clinical and economic burden of nonadherence with antihypertensive and lipid-lowering therapy in hypertensive patients | Q44099316 | ||
| Cost-effectiveness of a family and DNA based screening programme on familial hypercholesterolaemia in The Netherlands | Q44243122 | ||
| Cost-effectiveness of managing familial hypercholesterolemia using atorvastatin-based preventive therapy | Q46649931 | ||
| Cost-effectiveness of optimizing prevention in patients with coronary heart disease: the EUROASPIRE III health economics project | Q47327910 | ||
| Validation of health economic models: the example of EVITA. | Q47375894 | ||
| Changes to the statin prescribing policy in Belgium: potential impact in clinical and economic terms | Q47628067 | ||
| The German Coronary Artery Disease Risk Screening Model: development, validation, and application of a decision-analytic model for coronary artery disease prevention with statins. | Q51791173 | ||
| A health economic model to determine the long-term costs and clinical outcomes of raising low HDL-cholesterol in the prevention of coronary heart disease. | Q51926780 | ||
| Framingham risk function overestimates risk of coronary heart disease in men and women from Germany—results from the MONICA Augsburg and the PROCAM cohorts | Q52017724 | ||
| Primary and subsequent coronary risk appraisal: new results from the Framingham study. | Q52082530 | ||
| A comparison of economic modelling and clinical trials in the economic evaluation of cholesterol-modifying pharmacotherapy. | Q52249064 | ||
| Cardiovascular disease risk profiles. | Q52461317 | ||
| An updated coronary risk profile. A statement for health professionals. | Q52461335 | ||
| Are the Framingham and PROCAM coronary heart disease risk functions applicable to different European populations? The PRIME Study | Q57605872 | ||
| Cost-effectiveness of raising HDL cholesterol by adding prolonged-release nicotinic acid to statin therapy in the secondary prevention setting: a French perspective | Q57658420 | ||
| Probability of stroke: a risk profile from the Framingham Study | Q57746223 | ||
| Clinical benefits and cost-effectiveness of lowering serum cholesterol levels: the case of simvastatin and cholestyramine in The Netherlands | Q67278439 | ||
| Cost effectiveness of cholesterol-lowering therapy in The Netherlands. Simvastatin versus cholestyramine | Q69240392 | ||
| Cost-effectiveness of simvastatin versus cholestyramine: results for Sweden | Q74823175 | ||
| Profile for estimating risk of heart failure | Q77889326 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 4.0 International | Q34179348 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 2 | |
| P304 | page(s) | 205-213 | |
| P577 | publication date | 2018-02-01 | |
| P1433 | published in | PharmacoEconomics | Q7180778 |
| P1476 | title | Systematic Review of Validity Assessments of Framingham Risk Score Results in Health Economic Modelling of Lipid-Modifying Therapies in Europe | |
| P478 | volume | 36 |
| Q90392805 | Economic Modelling of Chronic Kidney Disease: A Systematic Literature Review to Inform Conceptual Model Design |
| Q92792357 | Noninvasive sublingual microvascular imaging reveals sex-specific reduction in glycocalyx barrier properties in patients with coronary artery disease |
| Q92894290 | The "inconvenient truth" about AI in healthcare |
Search more.